BioCentury
ARTICLE | Product Development

Why COVID master protocols haven’t been productive in the U.S., and how to fix it

The U.S. needs to prioritize master protocols for COVID and beyond

January 23, 2021 1:54 AM UTC

If the U.S. hopes to generate substantial, meaningful data on therapies for COVID-19 and future pandemics, it will need to overhaul the clinical trial ecosystem to prioritize master protocols. 

At least 10 master protocols for COVID-19 are up and running in the U.S., but nearly a year into the pandemic most have yet to produce actionable data...